全文获取类型
收费全文 | 113436篇 |
免费 | 11437篇 |
国内免费 | 8779篇 |
专业分类
耳鼻咽喉 | 981篇 |
儿科学 | 1078篇 |
妇产科学 | 1149篇 |
基础医学 | 13766篇 |
口腔科学 | 1944篇 |
临床医学 | 14986篇 |
内科学 | 16289篇 |
皮肤病学 | 1200篇 |
神经病学 | 6068篇 |
特种医学 | 4480篇 |
外国民族医学 | 78篇 |
外科学 | 11625篇 |
综合类 | 20552篇 |
现状与发展 | 40篇 |
一般理论 | 6篇 |
预防医学 | 7551篇 |
眼科学 | 3308篇 |
药学 | 11983篇 |
91篇 | |
中国医学 | 7054篇 |
肿瘤学 | 9423篇 |
出版年
2024年 | 153篇 |
2023年 | 1758篇 |
2022年 | 2779篇 |
2021年 | 5472篇 |
2020年 | 4706篇 |
2019年 | 3998篇 |
2018年 | 4163篇 |
2017年 | 3703篇 |
2016年 | 3549篇 |
2015年 | 5420篇 |
2014年 | 6639篇 |
2013年 | 5842篇 |
2012年 | 8513篇 |
2011年 | 9402篇 |
2010年 | 5920篇 |
2009年 | 4676篇 |
2008年 | 6048篇 |
2007年 | 5984篇 |
2006年 | 5796篇 |
2005年 | 5862篇 |
2004年 | 3809篇 |
2003年 | 3489篇 |
2002年 | 2987篇 |
2001年 | 2651篇 |
2000年 | 2794篇 |
1999年 | 2976篇 |
1998年 | 1978篇 |
1997年 | 2001篇 |
1996年 | 1544篇 |
1995年 | 1484篇 |
1994年 | 1288篇 |
1993年 | 808篇 |
1992年 | 990篇 |
1991年 | 796篇 |
1990年 | 671篇 |
1989年 | 647篇 |
1988年 | 542篇 |
1987年 | 474篇 |
1986年 | 415篇 |
1985年 | 317篇 |
1984年 | 158篇 |
1983年 | 129篇 |
1982年 | 80篇 |
1981年 | 91篇 |
1980年 | 62篇 |
1979年 | 57篇 |
1978年 | 11篇 |
1977年 | 6篇 |
1976年 | 7篇 |
1975年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Tie Zhou Shengfei Qin Weidong Xu Shouyan Tang Guanghua Chen Song Li Jianguo Hou Xu Gao Guowei Shi Zhongquan Sun Jie Jin Lijun Chen Weibing Sun Ben Liu Jingen Wang Qinggui Meng Dongwen Wang Zhiquan Hu Dalin He Yong Yang Xishuang Song Cheng Fu Yinhuai Wang Dingwei Ye Wei Zhang 《International journal of cancer. Journal international du cancer》2023,153(4):792-802
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177). 相似文献
102.
目的 探讨右美托咪定联合综合体温保护对腔镜手术治疗老年恶性肿瘤患者苏醒期质量及免疫功能的影响。方法 选择择期行腔镜手术治疗的老年恶性肿瘤患者90例,随机均分为3组:对照组(C组)、体温保护组(T组)和体温保护联合右美托咪定组(T-D组),每组30例。C组常规体温保护,T组和T-D组综合体温保护;T-D组麻醉诱导前10 min泵注右美托咪定0.5 μg/kg。记录3组患者麻醉诱导开始时(T0)、手术开始30 min(T1)、60 min(T2)、90 min(T3)、120 min(T4)以及手术结束时(T5)的鼻咽温度;于T0、术后2 h(T6)、24 h(T7)和48 h(T8)时抽取静脉血标本,测定T淋巴细胞亚群(CD3+、CD4+和CD8+)和自然杀伤细胞(NK cell)水平;记录患者术中麻醉药物用量及苏醒期质量指标。结果 与T0比较,C组T2~T5时点鼻咽温度均明显降低(P < 0.05);与C组比较,T组和T-D组T2~T5时点鼻咽温度明显升高(P < 0.05)。与T0时点比较,C组、T组和T-D组T6、T7和T8时点CD3+和NK cell活性均明显降低(P < 0.05);C组在T6、T7和T8时点,T组和T-D组在T6和T7时点,CD4+活性均明显降低(P < 0.05)。与C组比较,T组和T-D组T6和T7时点CD3+细胞活性均明显升高(P < 0.05);T组在T7时点,T-D组在T6和T7时点,CD4+细胞活性均明显升高(P < 0.05);T组在T7时点,T-D组在T6、T7和T8时点,NK cell活性均明显升高(P < 0.05)。结论 采用体温保护措施联合右美托咪定能够维持老年恶性肿瘤患者的体温稳定,减少围手术期意外低体温(IPH)的发生,并有效提高患者苏醒期质量,减轻免疫抑制程度,加速患者早期恢复。 相似文献
103.
目的 对比研究朝鲜淫羊藿酸性多糖酯化还原前后的理化特性,并探讨其改善油酸诱导的肝癌HepG2细胞脂质堆积活性的差异。方法 采用高效凝胶渗透色谱法测定朝鲜淫羊藿酸性多糖(EFPA)的均一性和分子量,高效液相色谱法测定EFPA和酯化还原后朝鲜淫羊藿酸性多糖(EFPA-R)的单糖组成;采用油酸(OA)处理HepG2细胞诱导建立脂质蓄积模型,不同浓度EFPA与EFPA-R(10、30、100、300 μg·mL-1)分别和OA共同作用于细胞24 h,采用CCK-8试剂盒测定细胞存活率,油红O染色观察细胞内脂滴蓄积情况,并采用试剂盒测定细胞内总胆固醇(TC)、甘油三酯(TG)含量。结果 EFPA为成分均一的多糖组分,分子量为125.8 kDa,由甘露糖、葡萄糖、半乳糖、葡萄糖醛酸和阿拉伯糖组成,摩尔比为1.7∶7.4∶1.4∶1.8∶1.0,葡萄糖占比最大,EFPA-R由甘露糖、葡萄糖、半乳糖和阿拉伯糖组成,摩尔比为0.8∶10.6∶2.1∶1.0;在10-300 μg·mL-1范围内,EFPA和EFPA-R对HepG2细胞的抑制作用较弱,作为给药浓度;与空白组相比,模型组细胞中TC、TG含量显著升高(P < 0.01),细胞内红色脂滴显著增多,与模型组相比,EFPA可显著降低细胞中TC、TG含量(P < 0.01),明显减少细胞内红色脂滴(P < 0.05或P < 0.01),EFPA-R干预后细胞则无明显变化。结论 EFPA可明显改善HepG2细胞脂质堆积情况,且呈现剂量依赖性,而半乳糖醛酸(GalA)的存在可能是其抑制HepG2细胞脂质蓄积的关键因素。 相似文献
104.
High-Order Positivity-Preserving Well-Balanced Discontinuous Galerkin Methods for Euler Equations with Gravitation on Unstructured Meshes 下载免费PDF全文
Weijie Zhang Yulong Xing Yinhua Xia & Yan Xu 《Communications In Computational Physics》2022,31(3):771-815
In this paper, we propose a high-order accurate discontinuous Galerkin
(DG) method for the compressible Euler equations under gravitational fields on unstructured meshes. The scheme preserves a general hydrostatic equilibrium state and
provably guarantees the positivity of density and pressure at the same time. Comparing with the work on the well-balanced scheme for Euler equations with gravitation
on rectangular meshes, the extension to triangular meshes is conceptually plausible
but highly nontrivial. We first introduce a special way to recover the equilibrium state
and then design a group of novel variables at the interface of two adjacent cells, which
plays an important role in the well-balanced and positivity-preserving properties. One
main challenge is that the well-balanced schemes may not have the weak positivity
property. In order to achieve the well-balanced and positivity-preserving properties
simultaneously while maintaining high-order accuracy, we carefully design DG spatial discretization with well-balanced numerical fluxes and suitable source term approximation. For the ideal gas, we prove that the resulting well-balanced scheme, coupled with strong stability preserving time discretizations, satisfies a weak positivity
property. A simple existing limiter can be applied to enforce the positivity-preserving
property, without losing high-order accuracy and conservation. Extensive one- and
two-dimensional numerical examples demonstrate the desired properties of the proposed scheme, as well as its high resolution and robustness. 相似文献
105.
106.
目的通过测量锁骨钩钢板内固定术后患者影像学资料,分析发生肩峰骨侵蚀的原因是否与钢板钩-肩峰匹配度相关。
方法回顾性分析2015年8月1日至2018年8月31日期间在上海市浦东医院骨科就诊的210例患者的影像学资料,210例患者均因肩锁关节脱位或锁骨远端骨折行锁骨钩钢板内固定治疗,其中男110例、女100例;年龄24~76岁,平均(44.60±8.75)岁;肩锁关节脱位70例,锁骨远端骨折140例。测量术后及终末随访患者肩锁关节正位X线片相关数据,按锁骨钩钢板术后是否发生肩峰骨侵蚀,将纳入患者分为3组:无骨侵蚀组(A组)、伴钢板钩移位骨侵蚀组(B组)、不伴移位的骨侵蚀组(C组),分别测量钢板钩-肩峰的匹配度(β),统计分析术后发生肩峰骨侵蚀与钢板钩-肩峰匹配度之间的关系。
结果纳入研究的210例患者术后随访24~64周,平均(32.0±6.5)周。A组患者115例,B组患者54例,C组患者41例。A组匹配度β(3.72±0.48)mm与B组β1(6.91±0.84)mm比较差异有统计学意义(P<0.05);A组匹配度β(3.72±0.48)mm与C组β2(5.88±0.65)mm比较差异有统计学意义(P<0.05);B组匹配度β1(6.91±0.84)mm与C组β2(5.88±0.65)mm比较差异有统计学意义(P<0.05)。
结论锁骨钩钢板内固定术后是否发生肩峰骨侵蚀与钢板钩-肩峰匹配度β存在明显相关性,钢板钩与肩峰之间的匹配度越好,β值越小,发生肩峰骨侵蚀的可能性更小。 相似文献
107.
目的分析热射病患者外周血单个核细胞转录组测序生物信息学结果,寻找影响热射病预后的关键基因。方法选取2019-06-01~2020-08-30空军军医大学附属西京医院急诊科收治的热射病患者,按照预后分为生存组和死亡组。随机数字法在两组中分别选取患者进行外周血单个核细胞转录组测序,生物信息学分析寻找差异基因;RT-PCR验证筛选出的差异基因在生存组和死亡组中的表达。结果29例诊断为热射病患者入选,按照预后分为生存组和死亡组,其中生存组18例,死亡组11例。随机数字法选取6例生存患者和4例死亡患者,外周血单个核细胞进行转录组测序,两组患者有693个基因表达有明显差异,通过生物信息学分析筛选出趋化因子(C-C基元)配体5(CCL5)、基质金属蛋白酶8(MMP8)、MMP9基因可能与预后相关。将两组外周血单个核细胞的目标基因表达情况通过RT-PCR法表达检测,与生存组比较,死亡组MMP8基因(P=0.8955)和MMP9基因(P=0.0597)表达无明显变化,CCL5基因表达明显上升(t=7.056,P<0.05)。结论CCL5基因可能是影响热射病预后的关键基因,需要进一步深入研究。 相似文献
108.
目的开发全结构化电子护理记录单,评价其应用效果。方法设计全结构化电子护理记录单并在南院区投入使用,北院区仍采用自由文本输入的方式记录电子护理记录单。实施1年后从2个院区各抽取230份出院病历对比护理记录,通过查看录像资料对比护士的记录效率。结果南院区护理记录结构正确率、符合专科护理指南率、护理诊断/评价及护理措施记录量与合格率显著高于北院区(均P<0.01);2个院区相同科室(内分泌科、儿科除外)护理记录时间比较,差异有统计学意义(均P<0.01)。结论全结构化电子护理记录单能提高护理书写质量和数据质量,但用于部分专科会增加记录时间,仍需要进一步优化。 相似文献
109.
110.
Yongfang Ma Ruyue Xu Xueke Liu Yinci Zhang Li Song Shuyu Cai Shuping Zhou Yinghai Xie Amin Li Weiya Cao Xiaolong Tang 《International journal of medical sciences》2021,18(6):1456
Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma; vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit, and Flt-3 signaling, is approved for treatment of advanced hepatocellular carcinoma (HCC). However, the benefit of sorafenib is often diminished because of acquired resistance through the reactivation of ERK signaling in sorafenib-resistant HCC cells. In this work, we investigated whether adding LY3214996, a selective ERK1/2 inhibitor, to sorafenib would increase the anti-tumor effectiveness of sorafenib to HCC cells.Methods: The Huh7 cell line was used as a cell model for treatment with sorafenib, LY3214996, and their combination. Phosphorylation of the key kinases in the Ras/Raf/MAPK and PI3K/Akt pathways, protein expression of the cell cycle, and apoptosis migration were assessed with western blot. MTT and colony-formation assays were used to evaluate cell proliferation. Wound-healing assay was used to assess cell migration. Cell cycle and apoptosis analyses were conducted with flow cytometry.Results: LY3214996 decreased phosphorylation of the Ras/Raf/MAPK and PI3K/Akt pathways, including p-c-Raf, p-P90RSK, p-S6K and p-eIF4EBP1 activated by sorafenib, despite increased p-ERK1/2 levels. LY3214996 increased the anti-proliferation, anti-migration, cell-cycle progression, and pro-apoptotic effects of sorafenib on Huh7R cells.Conclusions: Reactivation of ERK1/2 appears to be a molecular mechanism of acquired resistance of HCC to sorafenib. LY3214996 combined with sorafenib enhanced the anti-tumor effects of sorafenib in HCC. These findings form a theoretical basis for trial of LY3214996 combined with sorafenib as second-line treatment of sorafenib-resistant in advanced HCC. 相似文献